Sustained Delivery of Ocular Therapeutics

**OCR Number:** OCR 4994

**Description:**

Sustained delivery of ocular therapeutics by injectable, degradable microparticles.

**Advantages:**

- Sustained and local delivery without the use of implants negates frequent administration and reduces side effects
- Polymer/drug interactions and degradation tailored to direct delivery profile
- Formulations to deliver both hydrophobic and hydrophilic drugs
- All drugs and polymers have been previously FDA-approved

**Indications:** Glaucoma, diabetic retinopathy, uveitis, AMD

Stage of Development: Small animal studies showed sustained release of timolol over 90 days, triamcinolone over 5 months and methotrexate over 35 days. Larger animal studies in progress.

**Published/Issued Patents:** PCT App. Pub. No. WO2009143288,

**Published/Issued Patents:** U.S. App. Pub. No. 20110206773

**Publications:**

from poly (lactic-co-glycolic acid)/poly (lactic acid) microspheres for over 3 months. Journal of microencapsulation, 26(1), 18-26. [Pub Med]

**PI:** Erin Lavik

**Licensing Contact:** John Puziss

john.puziss@yale.edu